Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanofi-aventis has released Getgoal-L-Asia study results assessing the efficacy and safety of diabetes drug Lixisenatide, a once-daily GLP-1 receptor agonist, in combination with basal insulin.
Subscribe to our email newsletter
Results from the Phase III study showed that Lixisenatide once-daily in combination with basal insulin (with or without sulfonylurea) significantly improved glycemic control.
Sanofi-aventis R&D executive vice president Marc Cluzel said that the results of this study show that Lixisenatide once-daily in combination with basal insulin provides a significant reduction in A1C.
“Adding Lixisenatide, a new GLP-1 with post-prandial glucose effect, to a basal insulin may offer patients a new treatment approach to better control glucose and prevent long-term complications,” Cluzel said.
The Getgoal-L Asia study was a double-blind, placebo-controlled, two-arm parallel-group, multicenter trial and it assessed the safety and efficacy of Lixisenatide as add-on therapy in patients with type 2 diabetes insufficiently controlled with basal insulin (with or without sulfonylurea).
Reportedly, the study met its primary endpoint, and the addition of Lixisenatide once daily to basal insulin significantly reduced A1C levels by 0.88% versus placebo.